HIV Patient Management Solutions

Your mission for timely HIV monitoring impacting treatment decisions in regions hardest hit by the disease, is what drives Beckman Coulter Solutions.

AQUIOS CL

The AQUIOS CL Load & Go flow cytometer is an accurate solution that incorporates automated sample loading, data acquisition, data analysis, and is an LI system.

- Reducing potential user error by eliminating multiple manual steps to set up and run.
- Enhanced productivity with high-throughput performance by streamlining the least efficient features of existing systems.
- Learn in as little as one day for skilled flow cytometrists with computer based training videos.

AQUIOS CL FLG

A comprehensive suite of innovative products provides highly effective monitoring tools that can be taken closer to patients to accelerate time-to-treatment.

- Integrated fully automated sample preparation system - no sample preparation necessary, reducing operator exposure to pathogens.
- 72 h post draw testing window - permits accurate CD4 values on aged patient specimens to support even your remote blood draw needs.
- Simple, affordable testing - lowers CO4 testing costs, reducing overall patient costs.
- Less than 30 minutes to 36 h absolute CD4 values. Many laboratories report critical information while the patient is still on site.
- From 25 to 150 tests per day - a flexible instrument that meets your workflow requirements in centralized and more remote healthcare facilities.

AQUIOS TETRA

A fully automated Basic CD4 testing, and following exactly the same Load & Go principle, AQUIOS CL, offers additional options for advanced immunophenotyping:
- T-cells (CD3/CD4/CD8/CD315)
- B- and NK cells (CD19/CD56/CD3/CD315)

REVOLUTIONIZING LABORATORY WORKFLOW†

The DxN VERIS Molecular Diagnostics System

At Beckman Coulter Diagnostics, we are moving healthcare forward by bringing more than 80 years of automation and innovation history in the clinical diagnostics laboratory to the molecular diagnostics arena.

DESIGNED TO IMPROVE LABORATORY EFFICIENCY AND ACHIEVE FASTER RESULTS

SIMPLICITY AT WORK

- **Loading of consumables may be required.**

PUTTING THE POWER OF SCIENCE WHERE IT’S NEEDED MOST

Drawing on our history as leading biomedical life science companies, we’ve collaborated with healthcare leaders to develop breakthrough HIV monitoring solutions that contribute directly to the treatment process. Your mission for timely HIV monitoring impacting treatment decisions in regions hardest hit by the disease, is what drives Beckman Coulter. At Beckman Coulter, we’re bringing a world of care to a world in need.

REFERENCES

7. PLG: B43671: System Guide_PLG Application for the AQUIOS CL Flow Cytometer
9. 2015 Reports by Global Nexus for DxN VERIS

© 2016 Beckman Coulter. All rights reserved. Beckman Coulter and the stylized logo are trademarks of Beckman Coulter, Inc.
A LEGACY OF SERVING HUMANITY

The worldwide need for effective assessment and treatment is more urgent than ever, and Beckman Coulter is part of the solution. Beckman Coulter joined the race to combat the emerging threat of HIV/AIDS in the 1980s. Beckman Coulter introduced the manual CD4 counting test for use with a microscope for labs without access to flow cytometry. At Beckman Coulter Diagnostics & Life Sciences, we are moving healthcare forward by bringing more than 80 years of automation and innovation history in the clinical diagnostics laboratory from Flow cytometry to the molecular diagnostics arena.

BECKMAN COULTER JOINS THE FIGHT

By focusing on innovative, yet affordable solutions for HIV monitoring, Beckman Coulter supports the UNAIDS 90-90-90 target to ensure that by the year 2020, 90% of people living with HIV will know their HIV status, 90% of people with diagnosed HIV infection will receive sustained antiretroviral therapy, and 90% of all people receiving antiretroviral therapy will have viral suppression (2).

WHO GUIDELINES

The 2015 WHO guidelines, and the 2015 revision thereof, call for an earlier treatment with antiretroviral therapy (ART) for people infected with HIV, and identify CD4 count and viral load analysis as the two main technologies to monitor ART treatment initiation and follow-up (5; 6).

This requires countries to build capacity for the analysis of immune system integrity, and especially for CD4 analysis platforms that can be used in both centralised and regional healthcare facilities.

THE PLG CD4 TEST STORY

Monitoring CD4 lymphocyte count is essential in providing critical information that impacts patient care. CD4 monitoring allows caregivers to know significant changes in a patient's CD4 count, the progression so they can implement the most appropriate interventions (1).

Beckman Coulter has been providing cost effective solutions to monitor CD4 status in resource limited countries for several decades. The mounting HIV problem in these regions of the world has led to innovative solutions with a mission to deliver patient care.

An example of innovative solutions driven by need is the breakthrough ‘PanLeucoGating’ (PLG) story from South Africa. Developed by the University of the Witwatersrand, a leading South African research institute, PLG CD4 was adopted by the South African National Health Laboratory Service (NHLS). Today Beckman Coulter’s legacy and passion for science and innovation to improve healthcare manifests itself in the CARES Initiative.

AFFORDABLE, RELIABLE TESTING

By focusing on the most essential parameters—monitoring HIV testing, PLG CD4 analysis, cost, complexity, and the time previously required by labor-intensive processes to provide flow cytometry—laboratories with an affordable, high-performance testing solution that also standardizes automation and simplifies its efficient operation takes CD4 testing to new places (5).

Advantages of PLG CD4:

- Provides both CD4% and absolute counts
- Extends to accommodate sample age up to 72 hours
- Tiered laboratory network for smaller markets
- Provides both CD4% and absolute counts
- Extends to accommodate sample age up to 72 hours
- Tiered laboratory network for smaller markets
- Provides both CD4% and absolute counts
- Extends to accommodate sample age up to 72 hours
- Tiered laboratory network for smaller markets

The CARES INITIATIVE

The CARES initiative was launched and driven by a social and civic responsibility to support the fight against HIV/AIDS. Public and private partnerships are being explored to identify areas for Beckman Coulter to contribute for the broader community. We seek to develop alliances with non-governmental organizations (NGOs), implementing partners, and health policy organizations to align our efforts.

Beckman Coulter is meeting tomorrow’s needs today by our commitment to leading the fight against HIV/AIDS. Public and private partnerships are being explored to identify areas for Beckman Coulter to contribute for the broader community. We seek to develop alliances with non-governmental organizations (NGOs), implementing partners, and health policy organizations to align our efforts.

THE PLG CD4 TEST STORY

Monitoring CD4 lymphocyte count is essential in providing critical information that impacts patient care. CD4 monitoring allows caregivers to know significant changes in a patient’s CD4 count, the progression so they can implement the most appropriate interventions.

Beckman Coulter has been providing cost effective solutions to monitor CD4 status in resource limited countries for several decades. The mounting HIV problem in these regions of the world has led to innovative solutions with a mission to deliver patient care.

An example of innovative solutions driven by need is the breakthrough ‘PanLeucoGating’ (PLG) story from South Africa. Developed by the University of the Witwatersrand, a leading South African research institute, PLG CD4 was adopted by the South African National Health Laboratory Service (NHLS). Today Beckman Coulter’s legacy and passion for science and innovation to improve healthcare manifests itself in the CARES Initiative.

“With rising costs in the field, the need for a reliable test that is both accurate and cost-effective by its global effectiveness. In a new view, we found it. Ask any PLG CD4 test is doing better care to millions of patients worldwide.”

Professor Debbie Glencross

A sample plot from the peripheral blood of a normal donor is shown, depicting all white blood cells (CD45+), as well as a region to identify ‘PanLeucoGating’ (CD45/CD4). The lymphocyte (Lymphs) subpopulation for further analysis of CD4 cells. The name ‘Africa Gate’ stems from the form of the region that is depicted all white blood cells (CD45+), as well as a region to identify lymphocytes, monocytes, and granulocytes based on CD45 expression and cell complexity. Its efficient operation takes CD4 testing to new places.

Affordable, reliable testing is bringing better care to millions of patients worldwide.”

Professor Debbie Glencross

A sample plot from the peripheral blood of a normal donor is shown, depicting all white blood cells (CD45+), as well as a region to identify lymphocytes, monocytes, and granulocytes based on CD45 expression and cell complexity.

The PLG ‘Africa Gate’ is an example of innovative solutions driven by need. It is the breakthrough in providing critical information that impacts patient care. CD4 monitoring allows caregivers to know significant changes in a patient’s CD4 count, the progression so they can implement the most appropriate interventions.

The PLG CD4 test story from South Africa. Developed by the University of the Witwatersrand, a leading South African research institute, PLG CD4 was adopted by the South African National Health Laboratory Service (NHLS). Large-scale use of PLG CD4 has the potential to reduce the cost of HIV/AIDS monitoring.

PLG CD4 was subsequently licensed to Beckman Coulter for manufacturing and worldwide distribution. — with provision that the technology be made affordable for resource-limited countries. Beckman Coulter remains a proud partner to the NHLS. Today Beckman Coulter’s legacy and passion for science and innovation to improve healthcare manifests itself in the CARES Initiative.

THE PLG CD4 TEST STORY

Monitoring CD4 lymphocyte count is essential in providing critical information that impacts patient care. CD4 monitoring allows caregivers to know significant changes in a patient’s CD4 count, the progression so they can implement the most appropriate interventions.

Beckman Coulter has been providing cost effective solutions to monitor CD4 status in resource limited countries for several decades. The mounting HIV problem in these regions of the world has led to innovative solutions with a mission to deliver patient care.

An example of innovative solutions driven by need is the breakthrough ‘PanLeucoGating’ (PLG) story from South Africa. Developed by the University of the Witwatersrand, a leading South African research institute, PLG CD4 was adopted by the South African National Health Laboratory Service (NHLS). Large-scale use of PLG CD4 has the potential to reduce the cost of HIV/AIDS monitoring.

PLG CD4 was subsequently licensed to Beckman Coulter for manufacturing and worldwide distribution — with provision that the technology be made affordable for resource-limited countries. Beckman Coulter remains a proud partner to the NHLS. Today Beckman Coulter's legacy and passion for science and innovation to improve healthcare manifests itself in the CARES Initiative.